Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGAV | P06756 | 2/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19952916 | 1.00 | SIRT2 (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL19952843 | 1.00 | SIRT2 (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL19952918 | 1.00 | SIRT2 (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL5328141 | 0.95 | SIRT2 (0.66) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL5328146 | 0.95 | SIRT2 (0.66) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL918813 | 0.95 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL4958981 | 0.95 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL1021938 | 0.95 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL2467817 | 0.94 | FOLH1 (0.65) | SIRT2SIRT1FOLH1MAPTSYK | |
| SCHEMBL699636 | 0.94 | FOLH1 (0.65) | SIRT2SIRT1FOLH1MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| CN-110139644-B | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4138812-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | Temple University - Of The Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115461049-A | (S) -2-amino-6- ((3-aminopropyl) amino) hexanoic Acid (APL) for the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | 坦普尔大学 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021217006-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| CN-112088006-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-15 | — | — | CN | disclosed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| CN-110139644-A | For treating the composition and method of insulin resistance | 坦普尔大学 | 2019-08-16 | — | — | CN | disclosed |
| EP-3509575-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
| WO-2018049019-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, FABP4, SLC2A3 | SIRT2 449/4885SIRT1 464/4885FOLH1 2709/4885 |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | SIRT2 2326/4885SIRT1 1296/4885FOLH1 3978/4885 |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | SIRT2 2326/4885SIRT1 1296/4885FOLH1 3978/4885 |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | SIRT2 2326/4885SIRT1 1296/4885FOLH1 3978/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | SIRT2 2326/4885SIRT1 1296/4885FOLH1 3978/4885 |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | FABP1, AADAT, FABP6 | SIRT2 1299/4885SIRT1 1949/4885FOLH1 455/4885 |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | FABP1, AADAT, FABP6 | SIRT2 1299/4885SIRT1 1949/4885FOLH1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.